insurance, and 20.5 %, by central/local government funds (China 2008) .
Antenatal medical care coverage 99.99 % of the population in 2009, 78 % of mothers received postnatal care in 2009. The deliveries (5.51 %) were home deliveries or carried out in unregistered clinics. The women (90.96 %) made at least 1 visit to hospitals before delivery, and 3.53 % of pregnant women delivering at hospitals never visited hospitals during pregnancy. Total births (94.49 %) were attended by skilled health professionals in 2008. The attended delivery rate was 97.45 % in the urban areas, and it was 92.32 % in rural areas (China 2009a ).
Indicators of congenital/genetic "disease burden"
There are three national surveillance programs for birth defects and maternal and neonatal health: National Statistic of Health (assessed annually by the Ministry of Health), National Birth Registry (assessed by the Ministry of Public Security annually), and National birth defect registry (assessed by the Ministry of Health and National Population and Family Planning Commission annually). These surveillance networks were established in 1986. The information collected by these databases includes basic health indicators for infants and mothers. The period monitored by the National birth defect registry is from 7 days to 28 weeks after birth.
Nationwide population-based figures for all monitored birth defects was 5.6 % for 2011, and the overall number of birth defects identified during neonatal period rose from 109.79/10,000 for the year 2000 to 153.23/10,000 for 2011 (China 2012c) . As shown in Table 2 , congenital heart disorder (CHD), polydactyly, cleft lip/palate, neural tube defect, and hydrocephaly were included in the top ten common malformations between years 2000 and 2011. Notably, CHD accounts for 26.7 % of all birth defects identified (China 2012c) .
The incidence for these common malformations differs between urban and rural areas (Table 3) . Unlike the situation for NTD and limb reduction, the urban incidence of CHD is nearly twice as high as the rural.
The commonly occurring single gene recessive disorders for China include phenylketonuria (PKU), congenital hypothyroidism (CH), glucose-6-phosphate dehydrogenase (G6PD) deficiency, and thalassemia.
PKU and CH are the two conditions in the national mandatory newborn screening program of China. Two separate large scale epidemiological research studies revealed similar results regarding the incidences of PKU which are 1/13,699 (Wang 2011 ) and 1/11680 (Li 2011) . The national neonatal screening unit also published that the incidence of CH is higher in China (1/2,033) than in the USA (1/3,000-4,000), and Japan (1/7,000; Li 2011).
G6PD deficiency and thalassemia exhibited huge geographical variation. The China Ministry of Health (MOH) has not published national incidence or prevalence of these disorders, as the prevalence is much higher in southern China (Guangxi, Hainan, Yunnan, Guangdong and Guizhou province) . Many studies has shown that the carriers for either G6PD deficiency and thalassemia weight 5 % or more in southern China (Table 4) , and in some areas the carrier frequency can be over 20 % (China 2012c) .
Generally chromosomal abnormalities are responsible for about 85 % of miscarriages in China (Zhang et al. 2009 ). The most common chromosomal disorder in live births in China is Down syndrome (Zhu 2011) . The national incidence for (China 2007a) Down syndrome 4.7/10,000. The incidence of Down syndrome seems higher in urban areas than rural and mountainous areas (Xia et al. 2006) , and this is due to low recognition, resulting from limited healthcare and diagnostic service in rural and mountainous areas, especially in south-western China. Mid-term maternal screening and ultrasound screening for Down syndrome and other severe congenital malformations are performed for every pregnant woman in developed regions as a national mandatory program that allows 65 % (on average speaking) of Down syndrome identification during pregnancy (Zhu 2011) . Although advanced maternal age greatly increases the incidence of Down syndrome, over half of the babies with Down syndrome were born to mothers under 30 (Rosen and D'Alton 2005) .
Various disorders that have a genetic component only become apparent later in life. Due to the lack of awareness and incompetence in recognition, little data are available on these conditions, locally; Table 5 shows the prevalence of a few such disorders in China.
Percentage of all infant deaths due to congenital/genetic disorders
The overall rate of infant death in China is 0.9 % and for children under 5, the rate is 1.72 % (China 2010a) . The detailed percentage of all infant deaths due to congenital/genetic disorders is shown in Table 6 (China 2012c).
Estimated potential for reducing the proportion of infant deaths due to congenital and genetic disorders Dietary supplementation of folic acid greatly reduced incidence of NTD by over 62.3 % in China, especially in rural areas (72.7 %; China 2012c). Additionally salt iodinate supplementation also resulted in a drop of thyroid disease. Prenatal detection of CHD by ultrasonography allows early intervention via surgery. Newborn screening for PKU also allows early intervention of dietary treatment. The government initiated the PKU medical care scheme, providing free phenylalanine-free food for affected children.
Increased exposure to known risk factors that impact the incidence of congenital/genetic disorders at birth One of the most common teratogens identified in the country is cigarette smoke. The males (52.9 %) and 2.4 % of females are addicted to cigarette smoke, and 72 % of the non-smokers are endangered by passive smoking (China 2010a) . It has been clearly shown that both active and passive smoke could link to still birth, miscarriage, cleft lip, and/or palate (China 2010a) . Other teratogens associated with birth defects include syphilis, rubella infection, pesticides, epilepsy medications, radiation, and various chemical pollutions. (China 1994a ).
Availability of genetic services
Initially, prenatal and cytogenetic diagnostic programs began to be developed in the 1960s but were suspended by the riot of The Great Cultural Revolution until the 1970s. By then, advanced cytogenetic and molecular genetic services were gradually developed. Informal genetic counseling services began in the Hunan Province of China in 1973. At about the same time, chromosome laboratory studies had been initiated, and thereafter, genetic research laboratories were developed in some institutes and universities (Li et al. 1983) . In 1978, a series of training sessions for chromosome testing were held, and many cytogenetic laboratories were established afterwards. The first practice for molecular genetic diagnosis occurred in the mid 70s in Shanghai. This was the 1st stage of the development of medical genetic service in China. The second period was around the 1990s, when many institutions began to establish genetic laboratories. By the time of the 2nd national conference for medical genetics in 1992, genetic tests were available for over 20 genetic disorders, including Down syndrome and other chromosomal abnormalities, thalassemia, hemophilia, Huntington Disease, Duchene muscular dystrophy, spinal muscular atrophy, spinal cerebellum atrophy, and: PKU. The 3rd stage of development was after 2000, with the promotion of government regulations and many professional guidelines which standardize the medical genetic services. In this period, the style of development shifted from nongovernmental voluntary to governmental mandatory. To comply with governmental regulations, the diagnostic service provider was changed from institutions to the public health system. Currently, nearly all maternal and child health hospitals and all tier three hospitals are able to perform karyotyping and provide basic genetic counseling services. Some major metropolitan area hospitals utilized their financial and technical resources to set up genetic labs for indigenous diseases. In recent years, research institutions and universities are also joining in to play a role of developing new approaches and technology for detecting genetic diseases. The increasing governmental awareness of prevention/ intervention of birth defects and nation-wide surveillance will lead to faster development in the area of medical genetic service, and thus greatly benefit the public. Table 7 below shows the key genetic services available in China for different health purposes and in different types of settings. Genetic testing is now available for many common genetic disorders.
Although population and family planning clinics and maternal and child health hospitals are available throughout the country, and preconception tests are free of charge for Table 3 The differences of incidence of common malformations between urban and rural areas (China 2012c) The incidence is in 1/10,000 units everyone, the rate of using the services is very disappointing. There are three reasons:
1. The lack of governmental support for molecular genetic diagnosis: To ensure the service standard and coverage of neonatal screening, carrier screening and cytogenetic diagnosis, MOH has issued many guidelines and regulations (China 1995 (China , 2002b (China , 2007c (China , 2011a (China , 2003a (China , 2009c , but none of these was specific for molecular genetic diagnosis, which is thought to be the most integral component of genetic healthcare service. Without standards and increased governmental support, molecular genetic diagnostic services would be illegal. Such tests can only be carried out in academic institutions for non-clinical use. 2. The shortage in technical personnel: Unlike the developed countries, there is no education program designed for the training of medical genetic professionals. The technical personnel carrying out molecular genetic tests in the institutions are mostly educated overseas. It is impossible to gather a sufficient amount of highly educated professionals from abroad. 3. The lack of public awareness: In urban areas, most of the people are well educated. It is easy for them to understand and realize the usefulness of genetic service(s). But for those in rural areas and migrating working populations whose primary focus has been subsistence, intensive education and guidance are required.
The government of China has become well aware of the problems mentioned above. It has promulgated the existence of comprehensive genetic services and is committed to the perfection of comprehensive genetic services by establishing a nationwide network for the prevention and intervention of genetic disorders. It will implement effective measurements and procedures especially for the rural areas, and promote relative research and its translation to clinical use (China 2012c) .
Total number of genetic service facilities in the different health care settings
The maternal and child health care system has been successfully established in all areas of China. In this system, a provincial maternal and child health hospital, which is normally located in the capital city of the province, is in charge of other sub-level maternal and child health hospitals. According to the 2010 MOH annual report (China 2010a) , there are 3,018 maternal and child health hospitals (clinics) throughout the country.
There are 10,801 general hospitals (China 2010a ) with experts in gynecology, obstetrics and pediatrics who are providing genetic service(s) for the public. By 2012, over 600 prenatal screening/diagnosis centers, 185 neonatal metabolic disorder screening units, and 22,598 new-born blood spots sampling centers have been established nationwide (China 2012c) .
Other than the above clinical services, most of the molecular genetic tests were performed in academic settings. Nine institutions were able to provide such genetic service in China by 2008. The earliest was in Changsha, Hunan Province (Central South University); for Beijing and Shanghai, two were present in each city which are the Beijing Union Medical College, Peking University Center of Medical Genetics, Shanghai Medical Genetics Institute and Shanghai Tongji University. In Liaoning Province, two academic departments are offering genetic services, one was in Shenyang (National University in Medicine), and the other was in Dalian (Dalian Medical University). A center in Hangzhou, Zhejiang Province (University of Zhejiang) is also providing genetic services for the public, but all for non-clinical use.
Access to genetic services
Costs and reimbursement systems for genetic services available in China
The ordinary reimbursement system for health care services in China is the national social health insurance, which is still under development. It covers 97 % of the employed (including selfemployment) population, all the elders and children. The insurance reimburses 80-90 % of the cost if the service is approved by the insurance authority when the tests and treatment were carried out in the local public health system. In such cases, the reimbursement is transferred to the clinical center instantly and directly, and the patients only have to pay for the rest. The percentage reimbursement depends on the type of the insurance. If the tests and the treatment were taken at a clinical center in a different city from the one registered in the Most of the genetic counseling, prenatal and neonatal screening, prenatal ultrasound examination, and karyotyping for birth defects are approved by the insurance. The social health insurance system started working from the 1990s and was originally a designated health service for adults having a long-term employment. Since 2007, the social health insurance has been expended to all citizens, including children and elders. In less developed areas (mostly in the middle and west part of China), hospitals and clinic posts are providing free routine health check-ups for pregnant women when they are enrolled in the prenatal healthcare system that has been a local health promotion plan in most provinces. The pre-marital health examination is free to all, and in some provinces (e.g., Beijing and Guangdong) a preconception health examination is also fully covered by the government.
The potential barriers have been identified for people to access to genetic services within China
The potential barriers have been identified for people to access to genetic services within China. In addition, financial difficulty is a major barrier without doubt, particularly where the genetic tests are too costly for the patient and no medical aid covers the cost. The typical charge of a single molecular genetic test is 1,000-2,000 CNY, which is over half of the average monthly salary. Unbalanced distribution of genetic services and the large size of the country have resulted in that traveling to major hospital/institutions, a costly and time-consuming process for lower income families thus constituting a geographical and fiscal barrier. The ignorance of both health professionals and the public regarding the available genetic services and their value, may present a barrier to access, since the benefits may not be understood and referrals may not be made appropriately or may be made late. Lack of local expertise hinders the development of genetic services to the public; therefore sometimes the sample for molecular diagnosis has to be sent out to other centers for molecular diagnosis. Besides the above, a cultural issue is also a factor that should not be forgotten. For example, patients with a fatalistic attitude (faithful Buddhist and many other Chinese local beliefs) toward their health and pregnancy may prevent some Chinese people from utilizing genetic services. In addition, many patients use both Western medical and traditional Chinese herbal services (in some cases, spirit healer might also be a choice). In these situations, they may reject genetic services. The detailed barriers are listed below.
(a) Language-the official language of China is Mandarin, but only 53.06 % Chinese can communicate by Mandarin fluently; 86.38 % can speak one of seven very distinct accents. Fifty-three ethnic groups have their own language and written characters. Most of the languages for small ethnic groups are rich in daily life and psychology, but lack scientific words. The language 
barrier greatly reduces the promotion of reproductive health care services (Xu 2002; Qian et al. 2011 ). (b) Life style-life style of people also differs between ethnic groups, e.g., people of Mongolian Minority are nomads and good at keeping livestock. However, Tibetan has a completely different lifestyle and language (Xu 2002; Wu et al. 1999; Qiu et al. 2003) . (c) Belief-Apart from three major beliefs (Buddhism, Christianity, Islamism) of the world, which are present in China, Taoism is also a large belief group in China (Baidu 2012) . Some ethnic groups may also have their own figure of belief. Belief deeply influencing life styles, behavior, and dietary structures; and thus, may also affect the acceptability of the prevention and intervention procedures for genetic disorders (Dou 1991) . (d) Tendency-Although Chinese herbal medicine is deeply rooted in the population, the majority of people would like to consult both Western medical health professionals and traditional Chinese herbal medical doctors. This is particularly obvious in the older generation and in ethnic minorities, which resulted in difficulty to implement genetic services (Xu 2002) . (e) Physical status and genetics-Due to the large land and variety of ethnic background, physical status varies from the northern to southern areas of the country. For example, thalassemia and G6PD are the most common genetic conditions in the provinces of Guangdong and Guangxi on the south coast of China (China 2012c) , while clubfoot is much higher in Tibet Autonomous Region than other areas of the country although the underlying genetic mechanism is yet to be identified (Zhong and Zhao, unpublished data) .
State of genetic services
Human resources, education, and training
The number of registered medical professionals are accessed and published annually by MOH (Table 8 ). According to the governmental media's news, over 280 universities/colleges are qualified for giving 5-8 years higher education for the students who will be a medical doctor, and another 350 institutions are qualified for providing the training for nurses and technicians (Wu 2012 ). In 2012, 1.76 million students were enrolled in undergraduate medical-related courses (Wu 2012) . For all these medical students basic genetics is compulsory; some top universities (Peking University, Tsinghua University, Zhejiang University, Tongji University and Shanghai Communication University) also have a specially designed medical genetics program instead of biological genetics for the medical students, for whom the advanced medical genetics courses are implemented, as we have experienced, by adapting the current medical genetics textbook used for medical students and for medical genetics trainees in the medical schools of the USA (Zhong 2006 The brain drain/emigration of high-end health care personnel working in all fields of medical services is a problem for the country. Many outstanding doctors decided to move to developed countries for better working opportunities and higher salaries. In the top university like Peking University Health Center, at least 1/10 students go abroad after the completion of their education. On the other hand, scientists or medical doctors with a degree awarded by an overseas university cannot be accepted by MOH, and therefore, are not allowed to perform medical practice for the public.
Workload
The exact number of medical genetic centers in China is unavailable, as there is no official data available. By an Internet search, only nine university-bound medical genetic centers were found. In addition, most of the provinces have established at least one prenatal screening and one diagnostic center in major hospitals. These centers are regionally distributed throughout the country and communications are usually established on a basis of personal relations. Genetic counseling and karyotyping are routinely provided by all these centers either in universities or hospitals, but nearly all the DNA level genetic tests were performed in universities. The workload in all the centers is extremely heavy because of a lack of qualified staff. China has 13 billion people but is grossly understaffed in the field of medical genetics resulting in many unmet genetic health needs in local communities, although WHO has suggested that two medical geneticists and four genetic counselors are required to provide an adequate genetic service to every one million people (Wertz and Fletcher 2004) . Clinical genetic services, although limited, have been integrated into the public health system, in and around the academic centers of the universities and hospitals. Most genetic counseling clinics are held in public hospitals, especially maternal and child health hospitals. The medical genetic staff hardly ever undertake outreach visits due to limited resources, which have resulted in the majority of the population remaining underserved. The universal systematized prevention and surveillance of birth defects has been implemented since 1994. An efficient maternal and child healthcare system has been established from small towns to metropolitan cities, and the right to receive routine medical examination before/during pregnancy is protected by law and various regulations (China 1994b (China , 1995 (China , 2003a . Facilities for general prenatal care, including karyotyping, biochemical tests, ultrasonography screening, microbiological tests are present in all-level hospitals; however, authorized prenatal screening and prenatal diagnosis is only available in qualified centers that are evaluated and authorized by the government, such as The Department of Health at provincial level.
Laboratories for genetic services
Diagnostic genetic testing is performed mainly through the laboratories at the major hospitals that are affiliated with top-ranked universities such as Peking University, Peking Union Medical College, Fudan University, etc. Although the service is fully available and accessible, the majority of specimens processed by these laboratories are usually from the university-affiliated hospitals. Unlike in developed countries, specimens are not sent directly to the appropriate and centralized laboratory for genetic testing in China, even though the local laboratory may not be capable of performing the tests. Genetic testing is offered as part of a research program in medical schools in a certain number of universities. As the school research laboratory is not a government-approved diagnostic laboratory, no diagnostic result is authorized to be reported. However, the researchbased result is always confused with the diagnostic report. To overcome this, the Chinese MOH founded a National Center of Reproduction Technology in 2009, which will become a central diagnostic laboratory for genetic diseases. There are more than 60+ centers, with academic affiliations, performing diagnostic genetic testing services, on a service basis.
Along with the growing economy, hospital-based genetic testing is far behind market demands. For example, prenatal karyotyping of amniotic fluid has to be delayed for three months in quite a lot of prenatal centers even though the laboratory staff has to finish seven to eight patients' specimens per day routinely. The increased market demands have stimulated development of private laboratories, through which genetic tests, including cytogenetic, molecular, and metabolic tests, are offered. Postnatal specimens can be processed but only on a basis of a subcontract with a government-authorized prenatal center. Most of private independent laboratories are in central cities, like in Beijing, Shanghai, and Guangzhou, or in a science-park of national, provincial, or municipal developing zones. These private laboratories usually provide the services that are not covered by public centers for primary healthcare facilities that lack facilities and capacities. Although the money spent for the genetic testing in private services is usually not be reimbursed by social health insurance and the charge is usually higher than public services, it seems that out-of-pocket payment is affordable for those who are willing to proceed with the test. In fact, the number of people who are voluntarily looking for accurate and efficient genetic service is growing, which has stimulated Chinese healthcare reform and opened new revenue for economic development.
Paternal testing is a specialized service in China. It was initially performed by genetic laboratories in 1991 but centralized under the National Public Security system. Nowadays, without certification and authorization by this system, no laboratory is able to perform legally recognized paternal testing (China 2007b) .
Quality assurance of medical genetic services
Quality assessment schemes are available and the centers in hospitals are exposed to regular peer review and inspection. All clinical laboratories offering genetic diagnosis are required to meet the various standards of issued by MOH (China 1994c (China , 2002a (China , 1995 (China , 2002b (China , 2003a (China , 2003b clinical testing departments gained approval of ISO15189 (Accreditation Criteria for the Quality and Competence of Medical Laboratories) and a few them obtained credentials from American College of Pathologists (CAP) (China 2012b) . The documentation of testing process and data outcome generated from genetic services are handled individually by the providers.
National policies and legal frameworks
In the current existing national policy guidelines (China 1981 (China , 2011b , reducing birth defects and improving the birth quality have become the priority in maternal and child health services in China. The Law of the Peoples Republic of China on Maternal and Infant Health Care (China 1994b) clearly states a priority of healthcare for preconception, perinatally, pregnancy, at birth, infancy, and childhood. The Maternal and Child Health Law also guaranteed that everyone has access to health care.
The use of blood products, tissue, stem cells and gametes and zygotes in humans is carefully regulated. Any use or research of these materials requires written application to a local ethics committee.
Cultural and social issues pertaining to medical genetic services in China.
Research priorities in genetics/genomics
Current national policies for funding research in genetics/ genomics, priorities for funding, and funding mechanisms There is no policy in China specifically covering the funding for research in human/medical genetics. Governmental funding is channeled through Natural Science Foundation of China (NSFC) and the Ministry of Science and Technology (MOST). For 2009, the NSFC distributed 18.275 billion RMB (about 3 billion USD) (China 2012a) . The full funding scheme of NSFC consists of three groups: research projects (funding is limited to an individual project, similar to NIH RO1 mechanism), research scientist developmental project (funding is limited to a person or a group for a specific research project, similar to NIH R29 mechanism), and environment condition projects (funding is limited for improving and investigating laboratory's hardware condition, e.g., equipment). All three schemes are not specifically allocated to fund medical genetic research, but on a basis of scientific merit. The funding level differs by application and schemes. The financial support for an individual project is likely to range from 200 to 500 k RMB (30-70 k USD), including those projects considered as a priority and key research. Some large projects combine several key research institutions and involved a greater level of funding, such as "863 National Research Foundation" (National Advanced Technology Developmental Plan) and "973 National Research Foundation" (National Major Basic Research Developmental Plan), are funded directly by MOST. Both 863 and 973 are similar to NIH program project with U mechanism, which budget may be up to 50 million RMB and considered as the top funds in the country. Before the 863 and 973 program was released, lobbying of MOST was quite important. The MOST would also invite chief scientists to propose priority, on an annual basis, for 863 and 973 program. Once the proposal is received, MOST will organize a series of evaluations to decide the research priority to fund. Announcement of funding opportunity will be released after the priority is identified and a decision is made, but unfortunately it is very short notification and tightly close to the deadline of application submission. The applicant has to construct their research proposal according to the format of MOST within a very short time frame, which explains why so many applications do not consist of well developed scientific ideas and well designed approaches. For those applications that have been approved, funding to the investigators who need money to conduct their research, could be delayed. Usually the delay period could be from 6 to 12 months or longer. Occasionally, one could be notified with "surprising money" that suddenly becomes available and the investigators are required to submit their application within a few days. This type of funding usually does not require peer review, and grantees are usually the ones who have a strong connection with the funding agency. These abnormal processes are being corrected and the peer review process is improved, although a few unusual tracts are still influencing the review process. Generally speaking, the application could be awarded only if the application has been scored with three "A" or five "A," depending on whether there are three or five reviewers during the first round scientific review process. The second or third round is usually only for the large size collaborative projects such as 863 or 973 funds. MOH only functions as an agency to identify the clinical research priority, and not many medical geneticists are involved in the decisionmaking group. Local government agencies may also provide funds with a relative small budget, ranging from a few thousand to 50,000 RMB and the amount hardly goes over 100,000 RMB (∼15,000 USD) except for research that has been identified as a "key" project that could benefit the local or regional communities or economic development. The total amount may then reach 300,000 RMB (∼45,000 USD) for a 3-year project.
Research funding by private parties
Generally, private funding is not available to support research, except if it is contracted research for the funding agency. Most of time, the funds come from therapeutic or pharmaceutical companies for conducting clinical trials. There is almost no funding at all for medical genetics.
Known collaboration with international funding agencies
Chinese researchers in human genetics collaborate with international research teams and have received international funding from bodies such as the WHO, UNICEF, National Institute of Health (USA), Center for Disease Control (USA), the March of Dimes Foundation, Bill Gates Foundation, Welcome Trust, and the European Union.
Current centers of excellence in genetics/genomics research
There are several centers of excellence in the field of human genetics or medical genetics at present, most of which are located in metropolitan cities such as Beijing, Shanghai, Guangzhou, Chongqing, and other provincial capital cities. Almost all the centers are affiliated with either universities, China Academy of Medical Science, or China National Academy of Sciences. The most sounding genome center is the Beijing Institute of Genomics (BIG, http://www.big.ac.cn), the driving force for the human genome project in China, now moving towards translational medicine.
Regulation of translation of new genetic tests into health care practice
The Chinese Government always welcomes application of new technology. There is much funding available for the development of new technology and for translation to clinical fields. For example, on the national level, "863 Project" and "Natural Science Foundation of China (H20)." All the technology and instruments used in clinical areas are required to be approved by MOH, but a period of scientific and clinical trial is allowed, and the trial must comply with "The Regulation for Medical Equipment Clinical Trial" published by State Food and Drug Administration (China 2004) . Clinical technology itself has been classified into three groups by MOH, according to the safety, effectiveness, complexity, and level of ethical issue involvement of each technology. The higher level means more strict regulation. Despite the more complicated application progress, level two and three technologies are also required report the comprehensive progress of application to the approval issuing body (China 2009b) . As genetic testing is a level technology, the application procedure may only consist of clinical trial and evaluation. The typical length of time for obtaining an approval is 1.5-2 years.
Patient organizations and public education in genetics: The availability and structure of parent/patient organizations, including funding, objectives and provision of services Apart from China Foundation for Birth Defect Intervention and Aid, there is no official patient association organized by the government. There are over 30 national patient/family organizations for genetic disorders. All the organizations were registered as non-governmental and non-profit entities, which were then under the administration of the National Bureau of Public Organization, Ministry of Civil Affairs. Each organization consists of an operative board, which is formed by key and active members. Some groups (e.g., Autism Association, h t t p : / / a p p . a u t i s m . c o m . c n / en t e r p r i s e / j s p / s p e c i a l / autism.com.cn/index.jsp) also have a medical advisory board formed by medical professional and a few of them had a subcommittee of fundraising. The size of associations and groups vary largely due to the prevalence of disorders.
The purposes of most of the support groups are very similar, including raising public/government awareness, fundraising, offering support, providing suggestions, advice, and literature to affected individuals and their families, and supporting and stimulating relevant research.
The objectives of the supporting groups are very similar, and generally, they aim to: seek political legislation/policy support, raise awareness about the condition in the community; offer support, advice, and literature to affected individuals and their families; supporting and stimulating relevant research (mostly in academic centers, PKU Union, e.g., http://pkuunion.org/), where possible; training support parents; gaining support from interested medical experts; and making appropriate referrals.
The sources of funding and main activities of these organizations: Fund raising is generally undertaken in a very limited way, unless the association is well recognized and a financial professional is involved in the actual operation/organization of the association. Most support groups receive very little funds though various sources. Government seldom funds small public organizations. The majority of the funding is membership fees and donations. Where fundraising is undertaken, most funding comes from private businesses, corporate and individual donors, and in a few cases from international parties. Some large associations may have their own retailing or publishing company as their continuous solid source of funding.
The services offered by the groups/associations are generally appropriate to their objectives and include but not limited to:
a. providing condition-relevant literature and educating their members and the public b. organizing support group meetings c. giving training to patients or their parents to improve the quality of life d. providing psychosocial support, telephone/internet consultations e. raising funds to support more activities Relationship with clinical genetics community/health service: The National Bureau of Public Organization does not have any direct connection with clinical genetic services, rather through help from MOH. Individual associations usually have their own communication with either local clinical genetics and health service or higher-level facilities. Often, professionals of the clinical genetic services are invited to attend the association meetings. On the other hand, clinical geneticists and genetic counselors also keep in contact with the groups. Leaflets on the conditions are often produced in collaboration with the supporting parties; referrals are made to and from association members. So the relationship between the voluntary groups and the genetics professionals is generally good and that between the groups and the health department appears to be smooth and effective, particularly when a special clinic is dedicated to the management of a common condition in a tertiary public hospital setting.
Availability of primary prevention of congenital/genetic disorders via combinations of public and professional education programs Due to the increased awareness by the government, protocols have been developed to tackle congenital/genetic disorders. Unlike some countries, China supplies fortified basic food, including free folic acid supplement to women from 3 months before to 3 months after the beginning of pregnancy. The procedure has been carried out and carefully monitored for years and as a result, the incidence of neural tube defects has fallen by 62.3 % nationally, and by 70 % in some provinces with a higher incidence previously (China 2012c) . Also, salt has been iodized for many years thus preventing most cases of postnatal iodine deficiency disorders and goiter.
The National Population and Family Planning Commission has established an effective network deeply rooted in the public, even available in undeveloped areas. This network was originally founded for implementation of the "One Child Policy." But as the governmental attention shifted to birth defect prevention, the network was involved in many projects. By carefully designing the course, the network can maximize the effectiveness in the public education programs.
Professional and public education, covering recognition and prevention of congenital disorders, takes place at many levels. Medical/clinical professionals, including nurses, are all college/university graduates, which receive basic teaching in medical genetics during their degree and diploma studies, as well as in-service training held by individual hospitals during their employment.
Lay public groups, such as labor unions or women's unions in large entities or residential societies, patient organizations, may routinely organize talks from human genetics professionals. Although there is no proper genetic counseling as a profession currently in China, an obstetrician and gynecologist would take the role to give educational lectures to a number of professionals and the general public. Maternal and child health hospitals and other healthcare professional and governmental groups, such as voluntary groups like the Best Baby Association organized by the Peking University Center of Medical Genetics and the China National Commission of Population and Family Planning may compile leaflets for distribution on a number of common disorders, as well as on prenatal genetic diagnosis and genetic counseling services.
Conclusion
China is a fast-developing country with the largest population in the world. The economics and lives of people have been improved dramatically in the last 20 years. The Chinese government has given a great deal of attention since the founding of the Republic in 1949 to maternal and child health in the interest of protecting the health of mothers and children. In the last two decades, China has made substantial progress in reducing maternal, infant, and under-five mortalities.
Nevertheless, national figures for maternal and infant health indicators mask large disparities, which exist between urban and rural populations, and across different regions of China. Due to the limited access to the medical genetic service and antenatal/preconception care, maternal and infant death rates are highest among the rural, poor, and migrant populations, and in those regions, such as the western regions of China, with least access to antenatal and preconception care. The government needs to be better informed about the shortage of medical genetic professionals and the blanks in molecular genetic diagnostic service.
To tackle the problems above, the national government should take advantage of "single-party state," and provide more financial and technical support to less-developed areas, establish medical genetics occupation groups, including medical geneticists, genetic counselors, diagnostic laboratory personnel, and supporting personnel and launchrelated education programs, speed up the approval progress for molecular diagnosis and encourage the positive activities of the patient organizations, and promote direct research support in medical/clinical genetics.
The big gap between China and well-developed countries in genetic services cannot be filled in a short period time, but it is widely believed that that strong governmental support can effect rapid changes to benefit all of the people.
